Regional Meeting Series


Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.

Meeting Slides

Clinical Practice Guidelines

Considerations for Antiretroviral Use in Patients With Coinfections: Hepatitis C Virus/HIV Coinfection.

US Department of Health and Human Services (DHHS), 2017 (last updated March 2018).

Patients With HIV/HCV Coinfection.

American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA), 2017.

Clinical Resources

A Guide to Comprehensive Hepatitis C Counseling and Testing.

Centers for Disease Control and Prevention (CDC).

Beyond the Care Continuum: Addressing HIV/HCV Coinfection (pocket guide).

DHHS, 2017.

Database of Antiretroviral Drug Interactions.

HIV InSite. University of California, San Francisco, 2018.

Harm Reduction Coalition.

HEP Drug Interactions.

University of Liverpool, 2018.

Medical Provider Toolkit: Screening for Hepatitis C in People Living With HIV.

Project Inform, 2017.

Hepatitis C: The State of Medicaid Access. 2017 National Summary Report.

National Viral Hepatitis Roundtable (NVHR), 2017.

Understanding the Epidemic.

Centers for Disease Control and Prevention, 2017.

Patient Resources

Getting Off Right: A Safety Manual for Injection Drug Users

Harm Reduction Coalition. The Harm Reduction Coalition has produced a compilation of unbiased medical facts, injection techniques, and common sense with the goal of reducing harm and promoting individual and community health.

Hep C 123: Diagnosis, Treatment & Support

American Liver Foundation, 2018. The American Liver Foundation's Hep C 123 website is a dedicated online information and resource center created in support of individuals impacted by HCV infection.

Project Inform

Project Inform provides up-to-date information to help people living with HIV and HCV make the best choices regarding their treatment and care.

Hepatitis C and HIV Coinfection Booklets

Sex-C: Sex and Hepatitis C Prevention Tips for Gay Men

Sexual Transmission of Hepatitis C: A Guide for HIV-Positive Gay Men

Smartphone Pill-Reminder Apps (Free)

Mango Health — Medicine Manager, Pill Reminder for iPhone

Mango Health for Android 

Medisafe Pill Reminder, RX & Medicine Tracker for iPhone

Medisafe Meds & Pill Reminder for Android 

Suggested Readings

Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men: a systematic review and meta-analysis.

Hagan H, et al. AIDS. 2015;29(17):2335-2345.

Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012.

Suryaprasad AG, et al. Clin Infect Dis. 2014;59(10):1411-1419.

Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination.

Virlogeux V, et al. BMC Med. 2017;15(1):217.

Mechanisms of accelerated liver fibrosis progression during HIV infection.

Debes JD, et al. J Clin Transl Hepatol. 2016;4(4):328-335.

HCV coinfection contributes to HIV pathogenesis by increasing immune exhaustion in CD8 T-cells.

Rallón N, et al. PLoS One. 2017;12(3):e0173943.

Emerging and underrecognized complications of illicit drug use.

Wurcel AG, et al. Clin Infect Dis. 2015;61(12):1840-1849.

Attitudes and potential barriers towards hepatitis C treatment in patients with and without HIV coinfection.

Allyn PR, et al. Int J STD AIDS. 2018;29(4):334-340.

Behavioural, not biological, factors drive the HCV epidemic among HIV-positive MSM: HCV and HIV modelling analysis including HCV treatment-as-prevention impact.

MacGregor L, et al. Int J Epidemiol. 2017;46(5):1582-1592.

HIV/HCV co-infection: new guidelines, opportunities & challenges with the incarcerated population in the U.S.

Fisher N. HIV Specialist. 2017;9(1):16-19.

Barriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: a review.

Oramasionwu CU, et al. AIDS Patient Care STDS. 2014;28(5):228-239.

Effectiveness of all-oral antiviral regimens in 996 human immunodeficiency virus/hepatitis C virus genotype 1-coinfected patients treated in routine practice.

Bhattacharya D, et al. Clin Infect Dis. 2017;64(12):1711-1720.

HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?

Bruno G, et al. Int J Infect Dis. 2017;62:64-71.

Direct-acting antivirals improve access to care and cure for patients with HIV and chronic HCV infection.

Collins LF, et al. Open Forum Infect Dis. 2017;5(1):ofx264.

High hepatitis C cure rates among black and nonblack human immunodeficiency virus–infected adults in an urban center.

Falade-Nwulia O, et al. Hepatology. 2017;66(5):1402-1412.

Medical and behavioral approaches to engage people who inject drugs into care for hepatitis C virus infection.

Gonzalez SA, et al. Addict Disord Their Treat. 2017;16(2 suppl 1):S1-S23.

Interferon-free therapy for treating hepatitis C virus in difficult-to-treat HIV-coinfected patients.

Mínguez C, et al. AIDS. 2018;32(3):337-346.

Efficacy and safety of glecaprevir/pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 study.

Rockstroh JK, et al. Clin Infect Dis. 2018. (Epub ahead of print).

Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 study.

Younossi ZM, et al. Liver Int. 2017;37(12):1796-1804.

The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection.

Zeuzem S, et al. J Gastroenterol. 2018;53(5):679-688.

Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA.

Chhatwal J, et al. Aliment Pharmacol Ther. 2018;47(7):1023-1031.

The HCV care continuum does not end with cure: a call to arms for the prevention of reinfection.

Falade-Nwulia O, Sulkowski M. J Hepatol. 2017;66(2):267-269.

Treatment of HCV in persons who inject drugs: treatment as prevention.

Grebely J, Dore GJ. Clin Liver Dis. 2017;9(4):77-80.

Risk factors for hepatitis C virus reinfection after sustained virologic response in patients coinfected with HIV.

Young J, et al. Clin Infect Dis. 2017;64(9):1154-1162.

Interactive Presentation

Addressing Barriers and Challenges to HCV Elimination

Narrated by Robert Greenwald

Relevant Resources

PrEP for Your Patients’ Needs

The PCPs Role in Preventing HIV


Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV

Value-Based HIV Formularies

Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care

Targeting NASH

Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis

Hepatitis C is Curable

Got it? Treat it!

Real-World Issues in HIV Prevention & Treatment

The Critical Role of the Community Pharmacist

Evolving Models of HIV Care

Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box

The Nexus of NASH and Type 2 Diabetes Mellitus

The Emerging Role of the Diabetologist